Januvia, a widely used diabetes drug that generates $6 billion in annual sales for maker Merck, does not increase patients’ risk of being hospitalized for heart failure, a risk that did show up in clinical trials of competing drugs.
“We’ve teased this data backwards and forwards and everything comes up looking like the drug does not have a cardiovascular safety signal,” Eric Peterson, a Duke University cardiologist who co-led the study, told a press conference at the annual meeting of the American Diabetes Association in Boston.
Hey, check out all the research scientist jobs. Post your resume today!
